The Mt. Sinai researchers compared results from Theranos’ test with results from its rivals Laboratory Corp. and Quest Diagnostics. The study found Theranos sample collection had a higher rate of sample rejection. Additionally, the Theranos test gave cholesterol readings consistently five to 10 points too low, according to Forbes.
Theranos responded with a letter calling the study “flawed and inaccurate.” The company argues the study authors’ cholesterol readings were flawed as a result of their collection methods.
The study authors concluded laboratory practice standards would benefit from increased transparency and evaluation. Forbes concluded its article by calling for Theranos to make data on its tests public.
Click here to view the full study in The Journal of Clinical Investigation.
More articles on health IT:
5 thoughts on health IT & employee turnover
To pay or not to pay ransom: A tale of two hospitals
Nokia could break into health IT market
